

## Overview

### Useful For

Evaluating chronic lymphocytic leukemia patients at diagnosis or during disease course for the presence of *TP53* gene variants indicating high risk of disease progression and adverse outcomes

This test is **not intended for** the evaluation of patients suspected of having an inherited or germline *TP53* cancer syndrome (eg, Li Fraumeni syndrome)

### Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
CSP53	TP53 Pre-Analysis Cell Sorting, V	No	No

### Testing Algorithm

Flow cytometry will be performed on peripheral blood samples to verify diagnosis of chronic lymphocytic leukemia (CLL) and to selectively enrich for B cells in samples with a clonal population.

For more information see [TP53 Sequencing Testing Algorithm](#).

### Special Instructions

- [TP53 Mutation Testing Algorithm](#)
- [Molecular Hematopathology Patient Information](#)

### Highlights

This test is complementary to fluorescence in situ hybridization analysis for the 17p- abnormality but more appropriately identifies the presence of variant alteration and gene inactivation in tumor cells.

### Method Name

Polymerase Chain Reaction (PCR) and Sanger Sequencing

### NY State Available

Yes

## Specimen

### Specimen Type

Varies

---

**Ordering Guidance**

For the evaluation of patients suspected of having an inherited or germline *TP53* cancer syndrome (eg, Li Fraumeni syndrome), order one of the following tests containing *TP53*:

- XCP/ Hereditary Expanded Cancer Panel, Varies
- COMCP / Hereditary Common Cancer Panel, Varies
- BRGYP / Hereditary Breast/Gynecologic Cancer Panel, Varies
- CRCGP / Hereditary Gastrointestinal Cancer Panel, Varies
- PANCP / Hereditary Pancreatic Cancer Panel, Varies
- ENDCP / Hereditary Endocrine Cancer Panel, Varies
- THYRP / Hereditary Thyroid Cancer Panel, Varies
- WILMP / Hereditary Wilms Tumor Panel, Varies
- RENCP / Hereditary Renal Cancer Panel, Varies
- PRS8P / Hereditary Prostate Cancer Panel, Varies

**Shipping Instructions**

**Blood and bone marrow specimens must arrive within 10 days of collection.**

**Necessary Information**

**The following information is required:**

1. Pertinent clinical history
2. Clinical or morphologic suspicion
3. Date of collection
4. Specimen source

**Specimen Required**

**Submit only 1 of the following specimens:**

**Specimen Type:** Blood (preferred)

**Container/Tube:** Lavender top (EDTA) or yellow top (ACD solution B)

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**
3. Label specimen as blood.

**Specimen Stability Information:** Ambient/Refrigerate <10 days

**Specimen Type:** Bone marrow

**Container/Tube:** Lavender top (EDTA), yellow top (ACD solution B), or green top (heparin)

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. **Do not aliquot.**
3. Label specimen as bone marrow.

**Specimen Stability Information:** Ambient/Refrigerate <10 days

**Specimen Type:** Tissue

**Container/Tube:** Plastic container

**Specimen Volume:** 100 mg

**Collection Instructions:** Stabilize fresh tissue in tissue culture medium or freeze immediately after collection.

**Specimen Stability Information:** Refrigerate 24 hours/ Frozen

## Forms

- [Molecular Hematopathology Patient Information: B-Cell Chronic Lymphocytic Leukemia \(CLL\) for IGVH and/or TP53 Somatic Mutation Testing](#)
- If not ordering electronically, complete, print, and send a [Hematopathology/Cytogenetics Test Request \(T726\)](#) with the specimen.

## Specimen Minimum Volume

Blood, bone marrow: 1 mL

## Reject Due To

Gross hemolysis	Reject
Extracted DNA	Reject
Moderately to severely clotted Formalin-fixed paraffin-embedded tissue	Reject

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies	10 days	

## Clinical & Interpretive

### Clinical Information

Patients with chronic lymphocytic leukemia (CLL) have variable disease course influenced by a series of tumor biologic factors. The presence of chromosomal 17p- or a *TP53* gene variant confers a very poor prognosis to a subset of CLL patients, both at time of initial diagnosis, as well as at disease progression, or in the setting of therapeutic resistance. *TP53* gene variant status in CLL has emerged as the single most predictive tumor genetic abnormality associated with adverse outcome and poor response to standard immunochemotherapy; however, patients can be managed with alternative therapeutic options.

Although the prognostic relevance of an acquired *TP53* gene variant is best studied for CLL, similar findings are also

---

reported for other hematologic malignancies including low-grade B-cell lymphoma, diffuse large B-cell lymphoma, and some types of myelodysplastic syndromes and acute myeloid leukemia. Therefore, while this test has been developed to be primarily focused on high-risk CLL patients, *TP53* gene sequencing analysis can also be performed in additional neoplasms, as clinically indicated.

**Reference Values**

Genetic variants present or absent as compared to a reference sequence of the normal *TP53* gene

**Interpretation**

Results are reported in standard nomenclature according to the most recent Human Genome Variation Society recommendations and an interpretive comment regarding the nature of the sequence variant (eg, known deleterious, suspected deleterious, synonymous change) will be included to complete the clinical report.

**Cautions**

This test will not detect all possible acquired variants in the *TP53* gene because it is restricted to analyzing exons 4 to 9. However, this region encompasses more than 90% of described disease-causing variants and covers the coding exons of the critical DNA binding regions.

The analytical sensitivity of the assay can be affected by the absolute B-cell number in the peripheral blood or tissue sample, as well as the often subclonal nature of this tumor genetic abnormality. The assay attempts to compensate in part for this by performing an initial screening flow cytometry to assess B-cell quantity and by performing the cell enrichment step (for the peripheral blood specimens only) to isolate relatively pure CD19+ B cells for analysis. Nevertheless, the nature of the Sanger sequencing method is such that typical reproducible analytic sensitivity will be in the order of 25% variant allele burden.

Because optimal cell enrichment is dependent on the absolute B-cell quantity, samples with a very low white blood cell (WBC) or initial percentage of B cells (determined from flow cytometry or WBC automated cell count) will likely result in poor assay performance and inability to detect possible *TP53* gene variants in the tumor population.

**Clinical Reference**

1. Zenz T, Krober A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. *Blood*. 2008;112:3322-3329
2. Lehmann S, Oqawa S, Raynaud SD, et al: Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. *Cancer*. 2008;112:1296-1305
3. Rossi D, Cerri M, Deambrogi C, et al: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. *Clin Cancer Res*. 2009;15(3):995-1004
4. Zent CS, Call TG, Hogan WJ, et al: Update on risk-stratified management for chronic lymphocytic leukemia. *Leuk Lymphoma*. 2006;47(9):1738-1746
5. Trbusek M, Smardova J, Malcikova J, et al: Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. *J Clin Oncol*. 2011;29:2703-2708
6. Halldorsdottir AM, Lundin A, Murray F, et al: Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. *Leukemia*. 2011;25:1904-1908
7. Young KH, Leroy K, Moller MB, et al: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse

---

large B-cell lymphoma: an international collaborative study. *Blood*. 2008;112:3088-3098

8. Malcikova J, Tausch E, Rossi D, et al: ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation. *Leukemia*. 2018;32:1070-1080

## Performance

### Method Description

Peripheral blood specimens from chronic lymphocytic leukemia (CLL) patients only will be analyzed by a screening flow cytometry method to determine B-cell content and confirm the presence of a clonal B-cell population. Blood (but not bone marrow) samples from patients with CLL are enriched for B lymphocytes by cell sorting, and DNA is extracted from the B-cell fraction. For other sample types (bone marrow, fresh or frozen tissues) DNA is extracted directly without prior enrichment. Polymerase chain reaction and Sanger sequencing of *TP53* exons 4 to 9 is performed. Sequence analysis is performed using Mutation Surveyor and Alamut software. The presence of a detected variant is then assessed using curated public databases of known *TP53* gene mutations. (National Cancer Institute: The *TP53* Database. National Institutes of Health; 2022. Accessed October 5, 2022. Available at <https://tp53.isb-cgc.org/>; den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat*. 2000;15:7-12)

### PDF Report

No

### Day(s) Performed

Monday through Friday

### Report Available

8 to 14 days

### Specimen Retention Time

Blood/Bone marrow: 2 weeks; Extracted DNA 3 months

### Performing Laboratory Location

Rochester

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

---

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81352-TP53 (tumor protein 53) (eg, tumor samples), full gene sequence or targeted sequence analysis of >5 exons

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
P53CA	TP53 gene somatic mutation analysis	21739-8

Result ID	Test Result Name	Result LOINC® Value
MP018	Specimen Type:	31208-2
35759	Final Diagnosis:	34574-4
607075	Signing Pathologist	19139-5